Published in BMC Med Res Methodol on September 19, 2002
Prostate cancer mortality in areas with high and low prostate cancer incidence. J Natl Cancer Inst (2014) 2.16
Population screening for lung cancer using computed tomography, is there evidence of clinical effectiveness? A systematic review of the literature. Thorax (2007) 2.16
Breast cancer mortality in participants of the Norwegian Breast Cancer Screening Program. Cancer (2013) 1.25
Improving the biomarker pipeline to develop and evaluate cancer screening tests. J Natl Cancer Inst (2009) 1.24
Estimating the cumulative risk of false positive cancer screenings. BMC Med Res Methodol (2003) 0.98
Using observational data to estimate an upper bound on the reduction in cancer mortality due to periodic screening. BMC Med Res Methodol (2003) 0.98
Early reporting for cancer screening trials. J Med Screen (2008) 0.79
Meta-analysis of breast cancer mortality benefit and overdiagnosis adjusted for adherence: improving information on the effects of attending screening mammography. Br J Cancer (2016) 0.77
Comparing breast cancer mortality rates before-and-after a change in availability of screening in different regions: extension of the paired availability design. BMC Med Res Methodol (2004) 0.77
Cancer screening trials: nuts and bolts. Semin Oncol (2010) 0.76
Most breast cancer screening trials have a flawed design. Indian J Surg (2011) 0.75
Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet (1996) 20.53
Phases of biomarker development for early detection of cancer. J Natl Cancer Inst (2001) 10.37
All-cause mortality in randomized trials of cancer screening. J Natl Cancer Inst (2002) 8.93
Dangers of using "optimal" cutpoints in the evaluation of prognostic factors. J Natl Cancer Inst (1994) 7.91
A new design for randomized clinical trials. N Engl J Med (1979) 7.85
Adjusting for non-compliance and contamination in randomized clinical trials. Stat Med (1997) 4.08
The paired availability design: a proposal for evaluating epidural analgesia during labor. Stat Med (1994) 2.71
Markers for early detection of cancer: statistical guidelines for nested case-control studies. BMC Med Res Methodol (2002) 2.26
Meta-analysis adjusting for compliance: the example of screening for breast cancer. J Clin Epidemiol (1992) 1.40
Case-control studies of cancer screening: theory and practice. J Natl Cancer Inst (1998) 1.15
The paired availability design for historical controls. BMC Med Res Methodol (2001) 1.13
A likelihood ratio test for cancer screening trials. Biometrics (1995) 1.04
Evaluating the age to begin periodic breast cancer screening using data from a few regularly scheduled screenings. Biometrics (1998) 1.03
Evaluating serial observations of precancerous lesions for further study as a trigger for early intervention. Stat Med (2002) 1.01
Instrumental variables when evaluating screening trials: estimating the benefit of detecting cancer by screening. Stat Med (1999) 0.87
Design and analysis of cancer screening trials. Stat Methods Med Res (1995) 0.83
Issues in the mortality analysis of randomized controlled trials of cancer screening. Control Clin Trials (1994) 0.82
On the catch-up time method for analyzing cancer screening trials. Biometrics (1995) 0.81
Mortality results from a randomized prostate-cancer screening trial. N Engl J Med (2009) 30.05
Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. J Natl Cancer Inst (2012) 11.91
Colorectal-cancer incidence and mortality with screening flexible sigmoidoscopy. N Engl J Med (2012) 11.48
Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst (2008) 11.27
Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA (2011) 9.13
Screening by chest radiograph and lung cancer mortality: the Prostate, Lung, Colorectal, and Ovarian (PLCO) randomized trial. JAMA (2011) 6.45
The National Lung Screening Trial: overview and study design. Radiology (2010) 6.43
A common standard for conflict of interest disclosure in addiction journals. Addiction (2009) 5.62
New models for large prospective studies: is there a better way? Am J Epidemiol (2012) 3.85
Cumulative incidence of false-positive test results in lung cancer screening: a randomized trial. Ann Intern Med (2010) 3.79
Prostate cancer screening in the Prostate, Lung, Colorectal and Ovarian cancer screening trial: update on findings from the initial four rounds of screening in a randomized trial. BJU Int (2008) 3.51
American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. J Clin Oncol (2009) 3.51
Ovarian cancer screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial: findings from the initial screen of a randomized trial. Am J Obstet Gynecol (2005) 3.25
Race and colorectal cancer disparities: health-care utilization vs different cancer susceptibilities. J Natl Cancer Inst (2010) 3.16
Using relative utility curves to evaluate risk prediction. J R Stat Soc Ser A Stat Soc (2009) 3.04
Prostate biopsy following a positive screen in the prostate, lung, colorectal and ovarian cancer screening trial. J Urol (2005) 3.01
Prostate Cancer Screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: findings from the initial screening round of a randomized trial. J Natl Cancer Inst (2005) 2.82
Promoting healthy skepticism in the news: helping journalists get it right. J Natl Cancer Inst (2009) 2.82
Final results of the Lung Screening Study, a randomized feasibility study of spiral CT versus chest X-ray screening for lung cancer. Lung Cancer (2005) 2.79
Assessing contamination and compliance in the prostate component of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. Clin Trials (2010) 2.38
Lung cancer risk prediction: Prostate, Lung, Colorectal And Ovarian Cancer Screening Trial models and validation. J Natl Cancer Inst (2011) 2.31
Flexible sigmoidoscopy in the PLCO cancer screening trial: results from the baseline screening examination of a randomized trial. J Natl Cancer Inst (2005) 2.27
Screening for prostate cancer with PSA testing: current status and future directions. Oncology (Williston Park) (2011) 2.26
Markers for early detection of cancer: statistical guidelines for nested case-control studies. BMC Med Res Methodol (2002) 2.26
Baseline chest radiograph for lung cancer detection in the randomized Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. J Natl Cancer Inst (2005) 2.24
Serum prostate-specific antigen hemodilution among obese men undergoing screening in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Cancer Epidemiol Biomarkers Prev (2009) 2.20
Evaluating markers for the early detection of cancer: overview of study designs and methods. Clin Trials (2006) 2.10
Cumulative incidence of false-positive results in repeated, multimodal cancer screening. Ann Fam Med (2009) 1.94
American Society of Clinical Oncology provisional clinical opinion: chronic hepatitis B virus infection screening in patients receiving cytotoxic chemotherapy for treatment of malignant diseases. J Clin Oncol (2010) 1.91
Large-scale randomized prostate cancer screening trials: program performances in the European Randomized Screening for Prostate Cancer trial and the Prostate, Lung, Colorectal and Ovary cancer trial. Int J Cancer (2002) 1.89
The National Lung Screening Trial: results stratified by demographics, smoking history, and lung cancer histology. Cancer (2013) 1.76
Clinical cancer advances 2006: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. J Clin Oncol (2006) 1.64
Identifying genes that contribute most to good classification in microarrays. BMC Bioinformatics (2006) 1.60
National Lung Screening Trial findings by age: Medicare-eligible versus under-65 population. Ann Intern Med (2014) 1.56
Reported family history of cancer in the prostate, lung, colorectal, and ovarian cancer screening trial. Am J Epidemiol (2003) 1.52
Principles of cancer screening: lessons from history and study design issues. Semin Oncol (2010) 1.52
The word "cancer": how language can corrupt thought. BMJ (2013) 1.51
A perfect correlate does not a surrogate make. BMC Med Res Methodol (2003) 1.45
A population approach to precision medicine. Am J Prev Med (2012) 1.44
Overstating the evidence for lung cancer screening: the International Early Lung Cancer Action Program (I-ELCAP) study. Arch Intern Med (2007) 1.40
Lung cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. J Natl Cancer Inst (2010) 1.29
American Society of Clinical Oncology policy statement: the role of the oncologist in cancer prevention and risk assessment. J Clin Oncol (2008) 1.29
Clinical cancer advances 2007: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. J Clin Oncol (2007) 1.28
Estimating the cumulative risk of a false-positive test in a repeated screening program. Biometrics (2004) 1.27
Flexible sigmoidoscopy in the randomized prostate, lung, colorectal, and ovarian (PLCO) cancer screening trial: added yield from a second screening examination. J Natl Cancer Inst (2012) 1.27
Breast cancer epidemiology according to recognized breast cancer risk factors in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial Cohort. BMC Cancer (2009) 1.22
Biomarkers, subgroup evaluation, and clinical trial design. Discov Med (2012) 1.21
Colorectal cancers not detected by screening flexible sigmoidoscopy in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Gastrointest Endosc (2012) 1.18
National Children's Study: update in 2010. Mt Sinai J Med (2011) 1.17
Plausibility of stromal initiation of epithelial cancers without a mutation in the epithelium: a computer simulation of morphostats. BMC Cancer (2009) 1.15
Simple adjustments for randomized trials with nonrandomly missing or censored outcomes arising from informative covariates. Biostatistics (2005) 1.15
Cancer screening campaigns--getting past uninformative persuasion. N Engl J Med (2012) 1.14
Repeat prostate biopsy in the prostate, lung, colorectal and ovarian cancer screening trial. BJU Int (2007) 1.13
The fallacy of enrolling only high-risk subjects in cancer prevention trials: is there a "free lunch"? BMC Med Res Methodol (2004) 1.11
Paradoxes in carcinogenesis: new opportunities for research directions. BMC Cancer (2007) 1.10
Prostate-specific antigen velocity and prostate cancer gleason grade and stage. Cancer (2007) 1.09
Diagnostic procedures after a positive spiral computed tomography lung carcinoma screen. Cancer (2005) 1.08
Simple maximum likelihood estimates of efficacy in randomized trials and before-and-after studies, with implications for meta-analysis. Stat Methods Med Res (2005) 1.08
The transitive fallacy for randomized trials: if A bests B and B bests C in separate trials, is A better than C? BMC Med Res Methodol (2002) 1.08
Prostate volume and prostate-specific antigen levels in men enrolled in a large screening trial. Urology (2006) 1.07
Cancer screening in theory and in practice. J Clin Oncol (2005) 1.06
Prediction of true positive lung cancers in individuals with abnormal suspicious chest radiographs: a prostate, lung, colorectal, and ovarian cancer screening trial study. J Thorac Oncol (2009) 1.03
The prostate, lung, colon, and ovarian (PLCO) cancer screening trial: Status and promise. Urol Oncol (2004) 1.03
Prostate specific antigen changes as related to the initial prostate specific antigen: data from the prostate, lung, colorectal and ovarian cancer screening trial. J Urol (2006) 1.01
Does the source of death information affect cancer screening efficacy results? A study of the use of mortality review versus death certificates in four randomized trials. Clin Trials (2010) 1.01
Randomized trials, generalizability, and meta-analysis: graphical insights for binary outcomes. BMC Med Res Methodol (2003) 0.99
Using observational data to estimate an upper bound on the reduction in cancer mortality due to periodic screening. BMC Med Res Methodol (2003) 0.98
The prostate, lung, colorectal, and ovarian cancer screening trial and its associated research resource. J Natl Cancer Inst (2013) 0.98
Estimating the cumulative risk of false positive cancer screenings. BMC Med Res Methodol (2003) 0.98
5-α-Reductase inhibitors for prostate cancer chemoprevention: an updated Cochrane systematic review. BJU Int (2010) 0.97
Longitudinal evaluation of CA-125 velocity and prediction of ovarian cancer. Gynecol Oncol (2011) 0.93
Assessing the risk of ovarian malignancy in asymptomatic women with abnormal CA 125 and transvaginal ultrasound scans in the prostate, lung, colorectal, and ovarian screening trial. Obstet Gynecol (2013) 0.92
Adherence to repeat screening flexible sigmoidoscopy in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. Cancer (2002) 0.91
Lung cancer screening with low-dose helical CT: results from the National Lung Screening Trial (NLST). J Med Screen (2011) 0.89
Effect of length biased sampling of unobserved sojourn times on the survival distribution when disease is screen detected. Stat Med (2009) 0.88
Cancer prevention and the American Society of Clinical Oncology. J Clin Oncol (2004) 0.88
Alternative definitions of comparable case groups and estimates of lead time and benefit time in randomized cancer screening trials. Stat Med (2003) 0.87
Factors associated with human small aggressive non small cell lung cancer. Cancer Epidemiol Biomarkers Prev (2007) 0.87
Estimating the cumulative risk of a false-positive under a regimen involving various types of cancer screening tests. J Med Screen (2008) 0.87
Transparency and reproducibility in data analysis: the Prostate Cancer Prevention Trial. Biostatistics (2010) 0.86
Surrogate endpoint analysis: an exercise in extrapolation. J Natl Cancer Inst (2012) 0.86
Future directions for postdoctoral training in cancer prevention: insights from a panel of experts. Cancer Epidemiol Biomarkers Prev (2014) 0.85
Systems biology and cancer: promises and perils. Prog Biophys Mol Biol (2011) 0.85